EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies

Alireza Tojjari, Abdelrahman H Hafez, Ali Saeed, Meghana Singh, Anwaar Saeed

Frontiers in Bioscience-Landmark · 2024

DOI: 10.31083/j.fbl2907268 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Alireza Tojjari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA. Hauptthemen laut MEDLINE: Glypicans, Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver cancer, primarily hepatocellular carcinoma (HCC), is the second leading cause of cancer-related deaths globally. It is typically characterized by rapid progression, poor prognosis, and high mortality rates. Given these challenges, the search for molecular targets aiding early diagnosis and targeted therapy remains imperative. Glypican 3 (GPC3), a cell-surface glycoprotein, emerges as a promising candidate for addressing HCC Overexpressed in HCC tissues; GPC3 is a credible immunohistochemical marker for liver cancer diagnosis and a potential marker for liquid biopsy through soluble GPC3 in serum. Various immunotherapies targeting GPC3 have been developed, including vaccines, anti-GPC3 immunotoxins, and chimeric antigen receptor-modified cells. This review comprehensively covers the structure, physicochemical properties, biological functions, and clinical applications of GPC3. It explores diagnostic and treatment strategies centered around GPC3, offering hope for improved early detection and targeted therapies in the challenging landscape of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlypicansCarcinoma, HepatocellularLiver NeoplasmsImmunotherapyBiomarkers, TumorHumansMolecular Targeted TherapyPrecision MedicineCancer Vaccines

Stichwörter der Autor:innen

GPCHCCglypican 3immunotherapiesliver cancer

Substanzen

GlypicansGPC3 protein, humanBiomarkers, TumorCancer Vaccines

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA.
  • Faculty of Medicine, Al-Azhar University, 11651 Cairo, Egypt.
  • Department of Medicine, Ochsner Lafayette General Medical Center, Lafayette, LA 70503, USA.
  • UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.

Zitieren

APA

Tojjari, A., Hafez, A. H., Saeed, A., Singh, M., & Saeed, A. (2024). Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2907268

Vancouver

Tojjari A, Hafez AH, Saeed A, Singh M, Saeed A. Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2907268

BibTeX
@article{Tojjari2024,
  author = {Tojjari, Alireza and Hafez, Abdelrahman H and Saeed, Ali and Singh, Meghana and Saeed, Anwaar},
  title = {Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2024},
  doi = {10.31083/j.fbl2907268}
}
Kostenlos starten →